Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Calgon Carbon Corporation ( ( CCC - Analyst Report ) ) reported a profit of 20 cents per share in the first quarter of 2011 compared with 5 cents in the year-ago quarter. Reported earnings missed the Zacks Consensus Estimate by a penny.
Revenues
Sales in the quarter increased 9.5% to $135.3 million missing the Zacks Consensus Estimate of $138 million. Currency translation had a positive impact of $6.6 million on sales for the second quarter due to the weak dollar. Calgon Carbon’s performance for the quarter was solid, as sales strengthened and mix improved as the quarter progressed.
Sales in Calgon Carbon's biggest segment, Activated Carbon and Service, surged 10.1% to $121.5 million in the reported quarter. The increase was primarily attributable to higher sales of activated carbon products and increased services in three of its market segments -- environmental water, environmental air and food markets.
Equipment segment sales jumped 5.0% to $11.7 million due to higher revenue from ballast water treatment systems. However, Consumer segment sales for the quarter were almost flat at $2.1 million versus the prior year quarter.
Expenses
Cost of products sold increased 12.9% to $90.9 million in the reported quarter. Cost of products sold as a percentage of sales was 67.2% versus 65.2% in the year-ago quarter. Gross profit increased to $44.4 million in the quarter from $43.1 million in the prior-year quarter.
Gross margin was 32.8% in the quarter versus 34.8% for the second quarter of 2010. The decline was attributable to a $1.3 million charge related to the PreZerve product line, which was previously disclosed as being discontinued.
Selling, administrative and research expenses for the second quarter of 2011 were $22.5 million, versus $22.0 million in the comparable year-ago quarter. As a percentage of sales, SG&A improved to 16.6% in the second quarter of 2011 versus 17.8% in the second quarter of 2010.
Environmental and litigation contingencies in the second quarter of 2011 included a $1.3 million reduction in the estimate to complete a remediation project at the company’s production facility in Columbus, Ohio versus a $11.5 million litigation contingency charge in the second quarter of 2010.
Financial Performance
Cash and cash equivalents were $13.9 million as of June 30, 2011 compared with $34.0 million at the end of December 31, 2010.
Zacks Recommendation
We currently maintain a Zacks #3 Rank (short-term Hold recommendation) on Calgon and a long-term Neutral recommendation.
Competitors
Calgon competes with MeadWestvaco Corporation ( ( MWV - Analyst Report ) ) and ITT Water & Wastewater Herford GmbH.
Read the full Analyst Report on CCC
Read the full Analyst Report on MWV